Welcome to our dedicated page for Cumberland Pharmaceuticals SEC filings (Ticker: CPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Acetadote sales stack up against Caldolor launches or when Ifetroban clears its next FDA hurdle can feel like reading a foreign language. Cumberland Pharmaceuticals’ disclosures span clinical data, patent cliffs and global royalty agreements—details that easily bury the signal inside 250-page documents. This page turns that challenge on its head by offering Cumberland Pharmaceuticals SEC filings explained simply.
Every form you need is here the moment it hits EDGAR, and Stock Titan’s AI goes to work instantly. Need the Cumberland Pharmaceuticals quarterly earnings report 10-Q filing without hunting for brand-level revenue? We surface it. Want the Cumberland Pharmaceuticals annual report 10-K simplified so patent expirations and manufacturing risks are clear? Done. Surprise licensing deal? The Cumberland Pharmaceuticals 8-K material events explained module flags it with context. Our platform pairs real-time updates with AI-powered summaries, helping professionals focused on understanding Cumberland Pharmaceuticals SEC documents with AI save hours.
Monitoring leadership moves is equally direct. Receive alerts for Cumberland Pharmaceuticals insider trading Form 4 transactions, view Cumberland Pharmaceuticals Form 4 insider transactions real-time, and drill into Cumberland Pharmaceuticals executive stock transactions Form 4 before the market reacts. Compare incentive plans inside the Cumberland Pharmaceuticals proxy statement executive compensation to pipeline milestones, or run a Cumberland Pharmaceuticals earnings report filing analysis to track cash burn versus R&D progress. From 10-K risk factors to Schedule 13D activism, our comprehensive coverage and expert commentary keep you ahead—no more wading through jargon to find what matters.
SEC Form 4 filing dated 07/11/2025 reports a series of open-market purchases of Cumberland Pharmaceuticals Inc. (CPIX) common stock by director Caroline Young.
Transaction details:
- 20 separate buy transactions executed from 06/02/2025 to 06/30/2025.
- Total shares acquired: 84 (nineteen lots of 4 shares and one lot of 8 shares).
- Price range: $2.60 – $6.00 per share.
- Weighted-average purchase price: approximately $4.81 per share (derived from disclosed price and share data).
- Total cost: about $403.60.
All trades were automatically executed under a Rule 10b5-1 trading plan adopted on 11/14/2024, as noted in the Explanation of Responses.
Following the reported transactions Ms. Young’s direct beneficial ownership stands at 32,653 CPIX shares. No derivative security activity was reported, and the filing indicates that Ms. Young continues to serve as a director of the company.
The filing does not provide information on company operations, earnings or additional insider activity. The share-price pattern shows a steady decline over the month—from $5.20 on 06/02 to $2.74 on 06/30—suggesting the purchases occurred during a period of price weakness.
Cumberland Pharmaceuticals Inc. (CPIX) – Form 4 filing, 11 Jul 2025
Chairman, CEO and 10% owner A. J. Kazimi reported a series of open-market purchases carried out automatically under a Rule 10b5-1 trading plan adopted on 14 Nov 2024. Between 02 Jun 2025 and 30 Jun 2025 he bought about 160 common shares in 20 small daily lots (mostly 8 shares, last lot 16 shares). Purchase prices ranged from $6.00 at the start of the period to $2.60 at month-end, implying an average cost close to $5.0 per share (≈ $800 total).
Kazimi’s direct beneficial ownership increased from 5,699,268 to 5,699,428 shares. No derivative securities were involved. Because the transactions represent <0.003% of his existing stake and were pre-scheduled, the filing is largely administrative, although consistent insider buying—despite the share-price decline—can be viewed as a minor vote of confidence.
Cumberland Pharmaceuticals Inc. (CPIX) filed a Form 4 on 07/11/2025 disclosing insider purchases by director James Jones.
According to the filing, Mr. Jones bought 20 separate lots of 8 common shares each between 06/02/2025 and 06/30/2025 under a Rule 10b5-1 trading plan adopted on 11/14/2024. Purchase prices ranged from $2.60 to $6.00 per share, with the earliest trade executed at $5.20 and the lowest at $2.60, reflecting a notable intra-month share-price decline.
The aggregate acquisition totaled 160 shares, increasing the director’s direct beneficial ownership from 43,176 shares after the first trade to 43,336 shares after the final trade on 06/30/2025. No derivative securities were involved, and there were no dispositions.
While insider buying generally signals management confidence, the small trade size limits its quantitative impact. Nevertheless, the steady, automated purchases provide incremental insight into insider sentiment during a period of falling share prices.
Form 4 filing for Cumberland Pharmaceuticals Inc. (CPIX) details a series of open-market purchases executed by director Kenneth J. Krogulski under an existing Rule 10b5-1 trading plan adopted on 14 Nov 2024.
- Transaction window: 2 Jun 2025 – 30 Jun 2025 (20 trading days).
- Shares acquired: 935 common shares (19 trades of 45 shares each and one trade of 80 shares).
- Total cost basis: purchase prices ranged from $2.60 – $6.00 per share, indicating declining market prices over the period.
- Ownership change: holdings rose from 285,743 to 286,633 shares, a 0.3% increase.
- Transaction code “P” confirms open-market purchases; the “V” footnote references execution under the 10b5-1 plan.
No derivative securities were reported, and there were no dispositions. The filing is routine in nature and does not announce any corporate events, earnings data, or material changes beyond the incremental insider accumulation.
FAQ
What is the current stock price of Cumberland Pharmaceuticals (CPIX)?
What is the market cap of Cumberland Pharmaceuticals (CPIX)?
What does Cumberland Pharmaceuticals specialize in?
What are Cumberland's key products?
What is Cumberland's clinical pipeline focused on?
How does Cumberland differentiate itself in the pharmaceutical industry?
What is Ifetroban, and what conditions is it being developed for?
What international markets does Cumberland operate in?
What is unique about Cumberland's product Sancuso®?
What is the significance of Vibativ® in Cumberland's portfolio?
How does Cumberland support patient access to its products?
What is Cumberland Emerging Technologies (CET)?
